Marjorie Green, senior vice president and head of late-stage oncology, global clinical development, Merck Research Laboratories. "At Merck, we have a comprehensive development program across a broad range of gastrointestinal cancers with the goal of providing meaningful new options to patients and their healthcare providers," said Dr. "This approval of pembrolizumab plus chemotherapy offers patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction cancer a new immunotherapy regimen that has demonstrated the potential to help these patients live longer." Wainberg, professor of medicine at University of California, Los Angeles School of Medicine and co-director of the UCLA GI Oncology Program. "The majority of patients with gastric cancer are diagnosed at an advanced stage, at which point they face a poor prognosis with a five-year survival rate of 6%," said Dr. For more information, see "Selected Important Safety Information" below. Based on its mechanism of action, KEYTRUDA can cause fetal harm when administered to a pregnant woman. KEYTRUDA can also cause severe or life-threatening infusion-related reactions. Based on the severity of the adverse reaction, KEYTRUDA should be withheld or permanently discontinued and corticosteroids administered if appropriate. Early identification and management of immune-mediated adverse reactions are essential to ensure safe use of KEYTRUDA. Important immune-mediated adverse reactions listed here may not include all possible severe and fatal immune-mediated adverse reactions. Immune-mediated adverse reactions can occur at any time during or after treatment with KEYTRUDA, including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, dermatologic reactions, solid organ transplant rejection, and complications of allogeneic hematopoietic stem cell transplantation. Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue and can affect more than one body system simultaneously. Median overall survival (OS) was 12.9 months (95% CI, 11.9-14.0) for KEYTRUDA plus chemotherapy versus 11.5 months (95% CI, 10.6-12.1) for chemotherapy alone. The approval is based on data from the Phase 3 KEYNOTE-859 trial, in which KEYTRUDA plus chemotherapy reduced the risk of death by 22% (HR=0.78 p<0.0001) compared to chemotherapy alone for these patients. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma. RAHWAY, N.J., November 16, 2023-( BUSINESS WIRE)-Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy aloneĪpproval marks seventh gastrointestinal cancer indication for KEYTRUDA-based regimens and 38 th indication for KEYTRUDA in the US
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |